1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
STERIS plc

STERIS plc

STE
STERIS plcUS flagNew York Stock Exchange
210.19
USD
+0.43
- -
20.52BMarket Cap
STERIS plc
STE
(New York Stock Exchange)

Recent

price

210.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
20.36
24.1
25.76
27.51
31.14
31.67
30.57
30.81
32.9
35.75
36.47
43.3
45.5
52.01
55.37
60.45
60.42
Revenue per Share
0.86
2.33
2.74
2.2
2.27
1.57
1.29
3.42
3.59
4.81
4.66
2.5
1.07
3.83
6.23
7.97
7.96
Basic EPS, GAAP
0.68
1.42
2.41
2.09
2.71
1.81
2.94
3.44
4.14
4.44
5.29
4.07
3.96
6.2
7.89
9.9
9.9
Free Cash Flow per Basic Share
0.56
0.66
0.74
0.82
0.9
0.92
1.09
1.21
1.33
1.45
1.57
1.67
1.84
2.03
2.23
2.46
2.46
Dividend per Share
17.84
19.85
21.8
23.04
24.55
43.72
35.56
37.57
39.46
42.95
46.27
69.13
64.17
67.11
69.94
74.31
74.27
Book Value per Share
7.92
8.31
4.16
4.98
3.59
-3.41
-1.71
0.66
3.05
5.86
-0.39
-12.18
1.32
1.27
6.75
14.08
14.07
Tangible Book Value per Share
59
58
58
59
59
71
85
85
85
85
85
98
100
99
99
98
98
Basic Weighted Avg Shares
1,207
1,407
1,502
1,622
1,850
2,239
2,613
2,620
2,782
3,031
3,108
4,223
4,536
5,139
5,460
5,936
5,936
Sales/Revenue/Turnover
7.16
15.85
16.13
13.56
12.26
9.47
10.9
15.27
15.89
17.74
17.55
11.31
17.45
16.78
17.6
18.63
18.63
Operating Margin (%)
54
63
69
76
92
144
188
178
226
197
219
553
553
565
476
486
486
Depreciation Expense
51
136
160
129
135
111
110
291
304
408
397
244
107
378
615
782
782
Net Income, GAAP
30.55
35.52
29.56
31.29
35.32
35.08
40.08
17.85
17.42
18.22
23.32
22.45
18.24
21.27
23.2
25.04
25.04
Effective Tax Rate (%)
4.25
9.68
10.65
7.98
7.3
4.95
4.21
11.1
10.92
13.45
12.79
5.77
2.36
7.36
11.26
13.18
13.18
Profit Margin (%)
361
373
395
420
437
572
636
591
589
720
634
957
1,150
1,938
979
1,250
1,250
Working Capital
210
210
492
493
621
1,568
1,478
1,316
1,183
1,265
1,780
3,101
3,158
3,266
2,043
1,932
1,932
LT Debt
789
823
947
1,041
1,074
3,039
2,810
3,217
3,186
3,418
3,891
6,545
6,087
6,315
6,616
7,197
7,197
Total Equity
6.17
14.3
13.93
10.24
9.12
4.37
3.83
7.46
8.21
9.69
8.03
4.77
6.75
7.13
7.98
9.16
9.16
Return on Invested Capital (%)
5.23
10.91
10.91
7.86
7.49
4.08
2.95
7.33
7.51
9.3
7.98
3.98
2.02
4.98
7.1
8.92
8.92
Return on Capital (%)
5.52
12.28
13.17
9.85
9.59
4.87
3.59
9.33
9.3
11.68
10.48
4.57
1.63
5.81
9.09
11.02
11.02
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
35
34
155
LT Borrowings
1,897
1,898
1,813
LT Finance Leases
126
121
120
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
98
98
98
Market Capitalization
24,346
24,926
21,726

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,106
2,286
2,395
Cash, Cash Equivalents & STI
319
424
440
Accounts Receivable, Net
947
991
1,093
Inventories
658
674
632
Total Current Liabilities
889
922
1,145
Payables & Accruals
425
406
424
ST Debt
35
34
155
Deferred Revenue
50
59
59

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.56%
15.7%
8.79%
Free Cash Flow
25.39%
18.95%
24.99%
Net Income, GAAP
44.84%
49.69%
27.27%
Sales/Revenue/Turnover
10.62%
14.31%
8.73%
Total Cash Common Dividend
14.41%
12.66%
9.96%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,183
1,238
1,298
1,116
5,139
2025
1,280
1,329
1,370
1,481
5,460
2026
1,391
1,460
1,496
1,588
5,936

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.25
1.17
1.42
-0.01
3.83
2025
1.47
1.52
1.76
1.48
6.23
2026
1.8
1.95
1.96
2.25
7.97

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.47
0.52
0.52
0.52
2.03
2025
0.52
0.57
0.57
0.57
2.23
2026
0.57
0.63
0.63
0.63
2.46
Similar Companies
BrainCool AB (publ) (BRAIN.ST)
Establishment Labs Holdings Inc. (ESTA)
LexaGene Holdings Inc. (LXXGF)
Nemaura Medical Inc. (NMRD)
IRadimed Corporation (IRMD)
Computerized Thermal Imaging, Inc. (COIB)
Business
STERIS plc (NYSE: STE), headquartered in Dublin, Ireland, with U.S. operational headquarters in Mentor, Ohio, is a leading global provider of infection prevention, contamination control, and procedural support products and services to healthcare, pharmaceutical, medical device, life sciences, and industrial customers in more than 100 countries. Founded in 1985 as Innovative Medical Technologies, the company offers capital equipment including steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, automated washer/disinfectors, surgical tables, lights, booms, operating room integration systems, and automated endoscope reprocessors; consumables such as detergents, disinfectants, endoscopy accessories, barrier products, sterility assurance indicators, biological and chemical monitoring tools, sterilization pouches, and surgical instruments including V. Mueller, Snowden-Pencer, and Genesis brands; and services encompassing equipment installation and maintenance, instrument and scope repair, outsourced reprocessing, laboratory testing, contract sterilization via gamma irradiation, electron beam, ethylene oxide, and X-ray technologies, and gastrointestinal support solutions. STERIS operates through segments including Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies, targeting hospitals, surgery centers, medical device and pharmaceutical manufacturers, research facilities, and bioprocessing clients with a workforce exceeding 18,000 associates. Recent developments include the 2023 acquisition of Becton, Dickinson and Company's surgical instrumentation, laparoscopic, and sterilization container assets to expand healthcare offerings; facility expansions such as the 2025 openings of an ethylene oxide processing plant in Batu Kawan, Malaysia, and an X-ray processing addition in Suzhou, China; a 2024 business segment restructuring; and fiscal 2025 guidance projecting 8-9% revenue growth driven by consumables, services, and bioprocessing demand.

Company News

APIChat

  • zacks.com

    Here's Why Steris (STE) is a Strong Growth Stock

  • zacks.com

    Reasons to Retain STE Stock in Your Portfolio for Now

  • marketbeat.com

    STERIS Q4 Earnings Call Highlights

  • zacks.com

    STE Q4 Earnings & Revenues Miss, Stock Dips in Aftermarket Trading

  • seekingalpha.com

    STERIS plc (STE) Q4 2026 Earnings Call Transcript

  • zacks.com

    Steris (STE) Q4 Earnings and Revenues Miss Estimates

  • reuters.com

    Steris forecasts 2027 profit above estimates, banks on procedure-driven demand

  • globenewswire.com

    STERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year

  • globenewswire.com

    STERIS Appoints Pierre Boulud to Board of Directors

  • globenewswire.com

    STERIS Announces Dividend of $0.63 per share

  • zacks.com

    STERIS' Q4 Earnings on Deck: What's in Store for the Stock?

  • defenseworld.net

    Critical Contrast: Bluejay Diagnostics (NASDAQ:BJDX) & STERIS (NYSE:STE)

  • globenewswire.com

    STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026

  • defenseworld.net

    Rep. April McClain Delaney Buys Shares of Somnigroup International Inc. (NYSE:SGI)

  • defenseworld.net

    Rep. April McClain Delaney Buys Packaging Corporation of America (NYSE:PKG) Shares

  • defenseworld.net

    Tractor Supply (NASDAQ:TSCO) Stock Acquired Rep. April McClain Delaney

  • zacks.com

    Is This the Right Time to Hold STERIS Stock in Your Portfolio?

  • defenseworld.net

    Aberdeen Group plc Buys 20,097 Shares of STERIS plc $STE

  • defenseworld.net

    Assenagon Asset Management S.A. Cuts Holdings in STERIS plc $STE

  • seekingalpha.com

    Virtus SGA International Growth Q4 2025 Portfolio Activity And Performance